Blog
RSS FeedPosted by Michael Wonder on 23 Nov 2016
NICE reviews multiple myeloma drug and approves for routine use
23 November 2016 - Hundreds of patients set to benefit after NICE draft guidance recommends pomalidomide, a drug that treats some ...
Posted by Michael Wonder on 19 Nov 2016
Will NICE "go commercial"?
17 November 2016 - NICE, like the NHS it supports, is looking at how to make big savings. One option ...
Posted by Michael Wonder on 17 Nov 2016
Price discount helps give green light for breast cancer drug pertuzumab
17 November 2016 - NICE approves the third breast cancer drug is as many weeks as pertuzumab is recommended to shrink ...
Posted by Michael Wonder on 15 Nov 2016
NICE says pancreatic cancer treatment considered not cost effective for routine NHS use
15 November 2016 - The drug pegylated liposomal irinotecan, was not clinically effective enough to justify its high cost, NICE says ...
Posted by Michael Wonder on 15 Nov 2016
NICE publishes draft guidance on the use of Cinqaero (reslizumab)
15 November 2016 - NICE has published draft guidance on the use of reslizumab on the NHS. ...
Posted by Michael Wonder on 13 Nov 2016
Life-extending breast cancer drug approved by NICE in draft guidance
3 November 2016 - People with advanced breast cancer are set to benefit from a life-extending drug as NICE says it ...
Posted by Michael Wonder on 13 Nov 2016
Price cuts pave the way for routine access to breast and lung cancer drugs
10 November 2016 - People with breast cancer and lung cancer will have routine access to two life-extending treatments after the ...
Posted by Michael Wonder on 02 Nov 2016
Confounding by indication in clinical research
1 November 2016 - In the assessment of the effect of a treatment or potential risk factor—termed an exposure—on a patient ...
Posted by Michael Wonder on 02 Nov 2016
New expensive anti-cancer agents: which role is played by quality-adjusted life-years in the selection of a specific treatment?
1 November 2016 - Koczwara et al. emphasise that dissemination and implementation science should broaden its reach beyond its current geographic ...
Posted by Michael Wonder on 01 Nov 2016
NICE issues draft guidance on the use of ixekizumab
1 November 2016 - NICE has issued draft guidance on the use of Taltz (ixekizumab) for the treatment of patients ...
Posted by Michael Wonder on 01 Nov 2016
Head and neck cancer drug is not cost-effective
1 November 2016 - Cetuximab is not value for money says NICE in new draft guidance. ...
Posted by Michael Wonder on 29 Oct 2016
Cancer Drugs Fund: the bigger picture
26 October 2016 - Carole Longson and others from NICE welcome the authors’ creative ideas on the appraisal of cancer ...
Posted by Michael Wonder on 26 Oct 2016
NHS drug suppliers investigated over prices
26 October 2016 - Competition watchdog launches investigation after claims prices of 32 drugs rose 1,000% in five years. ...
Posted by Michael Wonder on 25 Oct 2016
NICE publishes draft guidance on the use of certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
25 October 2016 - Draft guidance supports the use of both bDMARDs. ...
Posted by Michael Wonder on 24 Oct 2016
UK Government publishes findings of Accelerated Access Review
24 October 2016 - The UK government has now published long-awaited findings of the independent Accelerated Access Review, which strives ...